Eli Lilly's Early Alzheimer's Treatment Donanemab Scores Japanese Approval, Its Second Largest Market
Eli Lilly's Kisunla (donanemab) has been approved in Japan for early symptomatic Alzheimer's, including mild cognitive impairment and dementia stages. The approval is based on data showing Kisunla slows disease progression and reduces amyloid plaque buildup.
Subtle changes in brain activity in the presence of both amyloid-beta and tau proteins may point to Alzheimer's disease, long ...
The Washington Post on MSN48m
Alzheimer’s patients and their families hear a new word: ProgressWhen Dennis Carr learned he had early Alzheimer’s disease, he immediately thought of his older brother who had died of the ...
Scientists at the West Virginia University Rockefeller Neuroscience Institute hope to unlock the true potential of drugs ...
The findings suggest that symptoms of Alzheimer's are closely linked to the makeup of the gut. Today, evidence strongly ...
Molina Healthcare boosts its support for Alzheimer’s Association with $170,000 donation for Walk to End Alzheimer’s events.
“Our discovery of RORB for these selectively vulnerable cells gives us the opportunity to study in detail exactly why they ...
The Walk to End Alzheimer's raised more than $137,600 to support the care, support and research programs of the Alzheimer's ...
An estimated 6.9 million Americans age 65 and older are living with Alzheimer's dementia today, according to the National ...
This past weekend was the annual Walk to End Alzheimer’s in Eagle. Every year, the event is gaining in attendance. We all are ...
Flowers decorated with names of loved ones spun in the wind, children ran around filling the sidewalks with affirming ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback